๐
Removab
catumaxomab
Ascites;Cancer
๐ซ Withdrawn
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Removab is indicated for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/removab